← All trials
NCT05154994
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Nov 30, 2023
- Completion date
- Nov 30, 2025
- First posted
- Dec 13, 2021
- Last posted
- Dec 17, 2021
- Enrollment
- 9
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of UtahLead sponsor
- National Cancer Institute (NCI)Collaborator
- University of UtahOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.